We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -124.00 | -1.12% | 10,978.00 | 10,974.00 | 10,978.00 | 11,098.00 | 10,878.00 | 11,060.00 | 1,459,543 | 12:48:00 |
| Industry Sector | Turnover (m) | Profit (m) | EPS - Basic | PE Ratio | Market Cap (m) |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | - | - | 212.2 | 51.8 | 170,049.22 |
From Oct 2022 to Oct 2023
By Elena Vardon
AstraZeneca PLC on Monday said its cancer drug Enhertu has shown clinically meaningful and durable responses across multiple HER2-expressing advanced solid tumors in its DESTINY-PanTumor02 Phase II trial.
The Anglo-Swedish pharma major said Enhertu--trastuzumab deruxtecan, which it is jointly developing and commercializing with Daiichi Sankyo--had met prespecified criteria for objective response rate and duration of response.
"Enhertu has already demonstrated its potential to improve outcomes for patients with HER2-targetable breast, gastric and lung cancers, and these positive initial results in other tumor settings with significant unmet need are very encouraging," said Chief Medical Officer and Oncology Chief Development Officer Cristian Massacesi.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
March 06, 2023 02:26 ET (07:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
| Your Recent History | |||||||
Register now to watch these stocks streaming on the ADVFN Monitor.
Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use. Log in to ADVFN
Register Now | |||||||
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
| V: gb D: 20231002 12:03:22 |
